12 results about "Receptor degradation" patented technology

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of a disease allele associated with muscle disease. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

The present disclosure relates to engineered antigen-binding molecules that include engineered single domain antibody variable domains having substituted cysteine residues. The engineered single domain antibody variable domains may form covalent or non-covalent inter-chain associations. Engineered antigen-binding molecules may include single domain antibody variable domains that target and are capable of agonizing a cell surface receptor and may be used, for example, in methods of agonizing certain receptors.

This invention discloses a recombinant protein pPIC9K-17, its preparation method, and its applications, relating to the field of gene recombination technology. The recombinant protein pPIC9K-17 provided by this invention does not strictly follow the (Gly-X-Y)n triple helix repeat pattern of traditional collagen in its core structural unit. The repeating unit sequence includes a "GAIQ" sequence and a sequence containing collagen characteristics, possessing a certain rigid structural basis and containing receptor-binding or signal activation domains for specific growth factors. The direct tandem connection of multiple such units theoretically enables multivalent binding, enhancing affinity and signal activation efficiency with cell surface receptors, thus surpassing the biological functional limitations of single components (pure collagen or pure growth factors) or simple repeating structures. The recombinant protein of this invention not only effectively promotes the proliferation and migration of skin fibroblasts and accelerates collagen synthesis, but also shows clear efficacy in promoting hair regeneration (hair growth), and can be used to prepare products for skin repair and / or promoting hair regeneration.

The application belongs to the technical field of biological medicine, and particularly relates to a recombinant collagen repair solution and a preparation method and application thereof. The application comprises the following steps: preparation of a protein activity enhancer; preparation of a recombinant humanized collagen fiber sol; and photo-polymerization construction of a recombinant humanized collagen hydrogel. The application is modified by sulfate esterification of pollen of apiaceae polysaccharide, and is compounded with the recombinant humanized collagen. The application can not only form a stable complex with the positively charged collagen amino acid residues through electrostatic interaction, maintain the natural triple helix conformation, reduce the aggregation and denaturation of the collagen, and enhance the activity of the collagen, but also can assist the recombinant humanized collagen in activating the cell surface receptors, enhancing the adhesion and proliferation of the cells, thereby enhancing the epidermal regeneration capacity of the recombinant humanized collagen, effectively improving the bioavailability of the recombinant humanized collagen at the wound site, and improving the repair and treatment effect on the wounded skin.

The present application relates to a compound or a pharmaceutically acceptable salt and / or solvate thereof comprising one or more circulation enhancing groups, one or more target binding groups, one or more chelating groups, at one least cleavable linker and at least one branching group that is at least trivalent. The application further includes a radionuclide complex or a pharmaceutically acceptable salt and / or solvate thereof, comprising a compound of the application or a pharmaceutically acceptable salt and / or solvate thereof, and one or more radionuclides, and to compositions comprising the compound or the complexes. The present application also includes methods of using the compounds, complexes and compositions for targeting and / or killing target cells. For example, the compound includes a compound of Formula I

The present application relates to a compound or a pharmaceutically acceptable salt and / or solvate thereof comprising one or more circulation enhancing groups, one or more target binding groups, one or more chelating groups, at one least cleavable linker and at least one branching group that is at least trivalent. The application further includes a radionuclide complex or a pharmaceutically acceptable salt and / or solvate thereof, comprising a compound of the application or a pharmaceutically acceptable salt and / or solvate thereof, and one or more radionuclides, and to compositions comprising the compound or the complexes. The present application also includes methods of using the compounds, complexes and compositions for targeting and / or killing target cells. For example, the compound includes a compound of Formula I

Disclosed herein are compositions and methods for modulating cell surface receptor signaling by specifically recruiting membrane phosphatases to a proximity of receptors of interest. This novel methodology, termed Receptor Inhibition by Phosphatase Recruitment (RIPR), represents a new approach to reducing and suppressing signal by receptors that signal through phosphorylation mechanisms. More particularly, the disclosure provides novel multivalent protein-binding molecules that specifically bind a cell surface receptor and antagonize the receptor signaling through recruitment of a phosphatase activity. Also provided are compositions and methods useful for producing such molecules, as well as methods for the treatment of diseases associated with the inhibition of signal transduction mediated by cell surface receptor.

The present disclosure provides polypeptides of netrin G1 (NetG1) and its cell surface receptor netrin G1 ligand (NGL1), and antibodies thereto, and methods of making such antibodies. The disclosure also provides uses of these NetG1 and NGL1 polypeptides, and antibodies thereto, in methods of treating cancers and diseases, including chronic fibrosis, inflammation, and inflammation-related diseases.

Described herein are compositions and techniques related to generation and therapeutic application of engineered extracellular vesicles. Engineered extracellular vesicles are vesicles (i.e., exosomes) comprising at least one engineered fusion polypeptide further comprising a vesicle targeting domain, scaffold linker domain, and signaling domain (i.e., a multi-effector signaling domain) wherein the signaling domain targets and interacts with a biological target, such as cell surface receptors. Said engineered fusion proteins can be organized in genetic vector constructs, expressed in mammalian cells, wherein the vesicle targeting domains anchor to extracellular vesicles such as exosomes, thereby presenting their joined multi-effector signaling domain which can relay a signal to target cells. Engineered extracellular vesicles adopt the hallmark biophysical and biochemical features of extracellular vesicles, allowing for rapid deployment and scale-up. Importantly, this strategy can allow for kinetically favorable signal generation and signal propagation to a target cell.

This application relates to oligonucleotides designed to target DMPK RNA (e.g., antisense oligonucleotides such as gapmer), targeted conjugates for delivering oligonucleotides to cells (e.g., muscle cells), and their uses, particularly in relation to the treatment of diseases. [Solution] In some embodiments, the muscle targeting agent specifically binds to internalized cell surface receptors on muscle cells. In some embodiments, the molecular payload inhibits the expression or activity of DMPK.